Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 15/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22608879 | 1.00 | RIPK1 (0.67) | RIPK1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL22608878 | 1.00 | RIPK1 (0.67) | RIPK1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL22608875 | 0.86 | RIPK1 (0.54) | RIPK1 | |
| SCHEMBL22608946 | 0.86 | RIPK1 (0.54) | RIPK1 | |
| SCHEMBL22608876 | 0.86 | RIPK1 (0.54) | RIPK1 | |
| SCHEMBL22608894 | 0.86 | RIPK1 (0.54) | RIPK1 | |
| SCHEMBL22608945 | 0.86 | RIPK1 (0.54) | RIPK1 | |
| SCHEMBL22608895 | 0.86 | RIPK1 (0.54) | RIPK1 | |
| SCHEMBL20165777 | 0.80 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL20165776 | 0.80 | RIPK1 (1.00) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192676-A1 | Heterocyclic Amides as Kinase Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-22 | — | — | US | claimed |
| EP-3732176-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2020-11-04 | — | — | EP | claimed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| US-20230192676-A1 | Heterocyclic Amides as Kinase Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-22 | — | — | US | disclosed |
| US-20230192676-A1 | Heterocyclic Amides as Kinase Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-22 | — | — | US | disclosed |
| US-20230192676-A1 | Heterocyclic Amides as Kinase Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-22 | — | — | US | disclosed |
| EP-3732176-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2020-11-04 | — | — | EP | disclosed |
| WO-2020043173-A1 | HETEROCYCLIC COMPOUND AS RECEPTOR INTERACTING PROTEIN 1(RIP1) KINASE INHIBITOR | 宁波文达医药科技有限公司 | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192676-A1 | Heterocyclic Amides as Kinase Inhibitors | MAP3K19, MAP3K20, MAP3K1 | RIPK1 416/4885KDM4E 669/4885MEN1 1652/4885 |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | RIPK1 1/4885KDM4E 2270/4885MEN1 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.